Arrowhead price target lowered to $77 from $83 at RBC Capital

RBC Capital analyst Luca Issi lowered the firm’s price target on Arrowhead (ARWR) to $77 from $83 and keeps an Outperform rating on the shares. The analyst cites the company having confirmed that Janssen (JNJ) is deprioritizing HBV as part of a broader strategic decision within infectious diseases. The firm remains positive on the stock however with the view that its A1AT will "ultimately be a drug", its cardiovascular assets are "relatively de-risked", and that its upcoming respiratory data may unlock value beyond liver.